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Research Article
LRRK2-phosphorylated Rab10 sequesters Myosin Va with
RILPL2 during ciliogenesis blockade
Herschel S Dhekne1,* , Izumi Yanatori1,* , Edmundo G Vides1 , Yuriko Sobu1 , Federico Diez2, Francesca Tonelli2 ,
Suzanne R Pfeffer1
Activating mutations in LRRK2 kinase causes Parkinson’s disease.
Pathogenic LRRK2 phosphorylates a subset of Rab GTPases and blocks
ciliogenesis. Thus, defining novel phospho-Rab interacting partners is
critical to our understanding of the molecular basis of LRRK2 patho-
genesis. RILPL2 bindswith strongpreference to LRRK2-phosphorylated
Rab8A and Rab10. RILPL2 is a binding partner of themotor protein and
Rab effector, Myosin Va. We show here that the globular tail domain of
Myosin Va also contains a high affinity binding site for LRRK2-
phosphorylated Rab10. In the presence of pathogenic LRRK2, RILPL2
and MyoVa relocalize to the peri-centriolar region in a phosphoRab10-
dependent manner. PhosphoRab10 retains Myosin Va over
pericentriolar membranes as determined by fluorescence loss in
photobleaching microscopy. Without pathogenic LRRK2, RILPL2 is not
essential for ciliogenesis but RILPL2 over-expression blocks cilio-
genesis in RPE cells independent of tau tubulin kinase recruitment to
themother centriole. These experiments show that LRRK2 generated-
phosphoRab10 dramatically redistributes a significant fraction of
Myosin Va and RILPL2 to the mother centriole in a manner that likely
interferes with Myosin Va’s role in ciliogenesis.
DOI 10.26508/lsa.202101050 | Received 8 February 2021 | Revised 26 February
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Introduction
Activating mutations in the LRRK2 kinase cause Parkinson’s disease
(Alessi & Sammler, 2018). Recent work has shown that pathogenic
LRRK2 phosphorylates a subset of Rab GTPases, including Rabs 8,
10, 12, and 35 (Steger et al, 2016, 2017) that are master regulators of
membrane trafficking events (Pfeffer, 2017). A significant conse-
quence of LRRK2 Rab phosphorylation is a decrease in primary cilia
in a variety of cell types, including in mouse brain (Steger et al, 2017;
Dhekne et al, 2018; Lara Ordónez et al, 2019). Phosphorylation of Rab
proteins blocks their abilities to interact with key regulators in-
cluding Rab GDI and the Rabin8 guanine nucleotide exchange
factor, as well as multiple, cognate Rab effector proteins (Steger
et al, 2016). This loss of effector binding alone would be sufficient to
interfere with Rab protein physiological functions. Importantly,
however, phosphorylated Rab proteins also show enhanced
binding to novel effectors, and understanding the roles of these
nascent interactions is critical to our understanding of the mo-
lecular basis of Parkinson’s disease pathogenesis.
RILP is a Rab7 effector and so-called, “cargo adaptor” that links
the microtubule-based motor proteins, dynein/dynactin to late
endosomes (Cantalupo et al, 2001; Jordens et al, 2001). RILPL1 and
RILPL2 are two RILP-related proteins that bind much more tightly to
phosphorylated Rab8 and Rab10 proteins than to their non-
phosphorylated forms (Steger et al, 2017), but little is known
about their cellular roles. Both RILPL1 and RILPL2 were reported to
be ciliary proteins involved in regulating ciliary content (Schaub &
Stearns, 2013). We showed previously that RILPL1 is relocalized
quantitatively to the mother centriole by (phosphorylated) pRab10
protein, and both pRab10 and RILPL1 (but not Rab8A) are essential
for the ability of pathogenic LRRK2 to block cilia formation (Dhekne
et al, 2018). In this study, we have investigated the possible role of
RILPL2 in contributing to a LRRK2-triggered cilia blockade.
RILPL2 is a Myosin Va (MyoVa)–interacting protein first reported
to be important for cell shape control and neuronal morphogenesis
(Lisé et al, 2009). RILPL2 interacts with the C-terminal, globular tail
domain (GTD) of MyoVa via its N-terminal RILP-homology “RH1”
domain (Lisé et al, 2009) and binds pRab8 and pRab10 (Steger et al,
2017) via its C-terminal RH2 domain (129–165; cf. Waschbüsch et al,
2020). Recently, RILPL2 has also been reported to regulate the
motor activity of MyoVa (Cao et al, 2019). By binding a myosin motor
at one end, and amembrane-anchored Rab at the other end, RILPL2
is an actin-based, motor-adaptor protein.
We have been studying the effect of Rab phosphorylation on
ciliogenesis and report here our progress in understanding the
consequences of pRab10-RILPL2 complex formation. We show that
the MyoVa GTD also contains a high affinity binding site for LRRK2-
phosphorylated Rab10, and LRRK2 kinase activity and pRab10 drive
MyoVa and RILPL2 to the mother centriole during ciliogenesis
blockade, retarding the release of MyoVa from that location.
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Quantitative analysis of Rab10 and MyoVa copy numbers in various
cell types indicates that a large pool of total MyoVa may be se-
questered under these steady state conditions.
Results
RILPL2 relocalizes to the mother centriole in serum starved cells
RILPL2 associates with primary cilia in IMCD3 cells (Schaub &
Stearns, 2013). We determined the localization of RILPL2 in pri-
mary astrocytes that were isolated using antibody immuno-
panning from brains of newborn rats (Foo et al, 2011). Most of
these astrocytes contain Arl13b+ primary cilia, and endogenous
RILPL2 was detected at low levels throughout the cytoplasm and
also at the base of these cilia (Fig 1A). Cultured cell lines, including
hTERT-(RPE) retinal pigment epithelial cells, yielded only weak
endogenous RILPL2 staining; however, upon exogenous expression,
HA- and GFP-RILPL2 displayed a diffuse, cytoplasmic localization
(Fig S1A and below). After 2 h of serum starvation to induce primary
cilia formation, a small amount of HA-RILPL2 was detected adjacent
to the mother centriole, identified by distal appendage protein
CEP164, or centriolar cap protein CP110 that labels both centrioles
(Fig 1B); partial RILPL2 re-localization upon serum withdrawal was
observed in >50% of the transfected cells (Fig 1C).
Upon live imaging of hTERT-RPE cells transfected with GFP-
RILPL2 and monomeric kusabira-orange (mKO2) tagged with the
centrosomal targeting sequence of Pericentrin/AKAP450 (PACT) to
provide a centrosomal marker (Gillingham & Munro, 2000), RILPL2
arrived at the mKO2-PACT+ puncta after ~3 h of serum starvation,
and remained associated with the centrosome for at least the next
5 h (Fig 1D and E). Thus, serum starvation increases the peri-
centriolar localization of RILPL2 protein.
LRRK2 activity relocalizes RILPL2 and MyoVa
We showed previously that LRRK2 kinase-phosphorylated Rab10 is
strongly relocalized to the pericentriolar region with RILPL1 protein
(Dhekne et al, 2018). Fig 2A shows an example of HeLa cells
expressing pathogenic R1441G-LRRK2–generated pRab10, that is
tightly concentrated on membranes surrounding Centrin 3–labeled
centrioles (Fig 2A). We explored the effect of LRRK2 activity on the
localization of RILPL2. In HEK293T cells expressing R1441G LRRK2 to
generate pRab10, RILPL2 localized tightly to perinuclear, pRab10-
positive structures (green, Fig 2B top row, Fig 2C and D), unlike the
distribution seen in wild-type cells (Fig S1A).
Most MyoVa is distributed diffusely throughout the cytoplasm (cf.
Fig S1A), but a small amount associates with primary cilia (Kohli
et al, 2017) and regulates ciliogenesis (Assis et al, 2017). In cells
expressing pathogenic LRRK2, MyoVa was redistributed to RILPL2
and pRab10-positive membranes (red, Fig 2B). Addition of the MLi-2
LRRK2 inhibitor for 2 h completely reversed the phenotype: pRab10
staining was lost and both RILPL2 and MyoVa proteins reverted to a
diffuse localization in 90% of cells (Fig 2B lower row; Fig 2C). Im-
portantly, localization of RILPL2 to the pericentriolar region did not
depend on MyoVa because three different shRNAs could deplete
MyoVa effectively (Fig 2E) and in these stable cell lines, RILPL2
clustering was unaltered (Fig 2D–F). Because we were unable to
detect endogenous RILPL2 in these cell types, these data reflect the
behavior of exogenous HA-tagged RILPL2 protein. Similar findings
were obtained for R1441C MEF cells (Fig S1B and C); HA-RILPL2 lo-
calized to numerous pericentriolar vesicles and its localization
became much less concentrated in the presence of MLi-2 to inhibit
LRRK2 activity. In addition, MyoVa knockdown (KD) in LRRK2-
expressing HEK293T cells did not alter the localization of pRab10
(Fig S1D and E). Altogether, these experiments show that RILPL2
relocalizes to pRab10-positive, pericentriolar membranes, inde-
pendent of MyoVa protein.
MyoVa also relocalizes to pericentriolar structures: although it
could be carried there by RILPL2 or Rab10 proteins (Lisé et al, 2009;
Roland et al, 2009), we show next that MyoVa binds directly to
pRab10 and relocalizes independent of RILPL2 protein (Fig S2D–F).
MyoVa GTD drives co-localization with MyoVa
Fig 3A diagrams the domain structure of Myosin V proteins. The
N-terminal motor domain is followed by a series of isoleucine-
glutamine (IQ) motifs and a set of variably spliced exons. At the C
terminus, the MyoVa GTD can interact with Rab3A (Wöllert et al,
2011), Rab11 (Roland et al, 2009; Lindsay et al, 2013; Pylypenko et al,
2013, 2016), and with Rab27A via the Slac2/Melanophilin adaptor
(Fukuda et al, 2002; Hume et al, 2002; Wei et al, 2013) in different cell
types. Importantly, Exon D that is conserved in all Myosin V isoforms
contains a binding site for Rab10 (Roland et al, 2009). Exon D-
containing forms of MyoVa are expressed broadly, but not in brain
or endocrine/neuroendocrine cells (Seperack et al, 1995; Roland et
al, 2009). We, therefore, created a MyoVa truncation construct that
deletes Exon D (MyoVa ΔD lacking amino acids 1,320–1,345) and a
construct to express the GTD alone (residues 1,421–1,880; Fig 3A).
In HEK-293T cells, mCherry-tagged versions of MyoVa FL (full
length MyoVa) and GTD were mostly cytosolic (Fig 3B). When MyoVa
FL was co-expressed with GFP-Rab10, more of it re-localized to
perinuclear, Rab10 containing vesicles (Fig 3C top row), consistent
with its established binding capacity. In contrast, Exon D–deleted
MyoVa (MyoVa ΔD) showed much less colocalization with GFP-
Rab10 (80 versus ~30%, Fig 3C lower row, Fig 3E). Surprisingly, ex-
pression of R1441G pathogenic LRRK2 relocalized bothMyoVa FL and
MyoVa ΔD to perinuclear membrane structures positive for pRab10
(Figs 3D and S2A). Quantitation revealed that MyoVa colocalized
with pRab10 to almost the same extent, with or without Exon D (Fig
3E). Importantly, even the normally diffuse GTD (Fig 3B) re-
distributed to pericentriolar, pRab10+ membranes (Fig 3F): 35% of
total MyoVa GTD colocalized with pRab10, whereas ~80% of pRab10
co-localized with GTD (Fig 3G). These values match closely the
extent of RILPL2 relocalization seen in earlier experiments (Fig 2).
Finally, endogenous MyoVa also co-localized with pRab10 in LRRK2
G2019S+/− primary astrocytes and GFP-R1441G-LRRK2 expressing
HEK293T cells (Fig S3A and B).
The ability of pRab10 to relocalize both MyoVa ΔD and the GTD
suggested that the MyoVa GTD might also contain a pRab10-specific
binding site. Therefore, we tested the requirement for Rab10 protein
to drive full-length MyoVa ΔD or GTD relocalization in R1441G
LRRK2–expressing 293T cells (Fig 4). Whereas control cells showed
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tight perinuclear GTD staining that was coincident with pRab10,
cells treated with two different Rab10 shRNAs showed no pRab10
staining and a diffuse GTD localization (Fig 4A, C, and E). Rescue with
Myc-Rab10 protein restored the original, concentrated GTD lo-
calization (Fig 4B, D, and E). Rab10 depleted cells also showed
dispersed full length MyoVa mCherry (Fig S2A) as well as dispersed
GFP-RILPL2 (Fig S2C). Thus, the GTD requires Rab10 protein for
pericentriolar localization; it appears not to require RILPL2 as
RILPL2 depletion in R1441C MEF cells did not alter GTD localization
(Fig S2D–F).
Figure 1. RILPL2 re-localizes to the mother centriole
in serum-starved cells.
(A) Primary, wild type rat astrocytes were fixed with 3%
PFA and stained for cilia using mouse anti-Arl13b
(green) and rabbit anti-RILPL2 (red). Box indicates
the region enlarged in the image shown at right. Bar,
10 μm. Arrows indicate the base of the cilium. (B) hTERT-
RPE cells were transfected with HA-RILPL2 at 80%
confluency and 24 h later either medium changed
(+FBS) or serum starved (−FBS) for 2 h. Cells were fixed
with −20°C methanol for 2 min and stained with
rabbit or mouse anti-HA to detect RILPL2 (red) and
mouse anti-CEP164, or rabbit anti-CP110 (green). Arrows
indicate the location of the centriolar region. Bar,
2.5 μm. (C) Quantitation of percent of cells that show
centriolar localized RILPL2 ± 2 h serum starvation.
Significance was determined by t test; *P = 0.03. Error
bars represent standard error of the mean from two
independent experiments with >50 cells per condition.
(D) hTERT-RPE cells expressing mKO2-PACT
(magenta) were transfected with GFP-RILPL2 (green).
Cells were serum starved and 15 min later imaged by
capturing Z-stacks every 6 min for the next 8 h.
Yellow arrowheads indicate the location of the
centrosome as marked by mKO2-PACT. Upper panel
shows GFP-RILPL2 in grayscale. Scale bar, 5 μm.
(E) Times at which GFP-RILPL2 appeared at the mKO2-
PACT structure. Error bar represents standard error of
the mean.
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Purified MyoVa GTD binds phosphorylated Rab10 directly
Co-immuno-precipitation experiments in cells expressing R1441G
LRRK2 confirmed binding of the MyoVa GTD to pRab10. As shown in
Fig 5A, full-length MyoVa mCherry bound both Rab10 and pRab10;
binding of both forms decreased in the presence of MLi-2 LRRK2
inhibitor, suggesting that pRab10 was a significant contributor to
MyoVa binding. Similarly, MyoVa ΔD lacking the D exon–Rab10
binding site still bound roughly the same amount of pRab10 and
less total Rab10 protein (Fig 5A and B). These experiments strongly
suggest that MyoVa ΔD contains an additional binding site with
preference for pRab10. Indeed, similar analysis of binding to the
GTDdomain in cell extracts (Fig 5C) confirmed co-immunoprecipitation
of Rab10 and pRab10 binding to the GTD, both of which were com-
pletely lost upon LRRK2 inhibition.
In experiments in which we monitored binding to RILPL2-GFP, MyoVa
GTDboundwithorwithout LRRK2activity, butwedetectedabout twiceas
muchMyoVa GTD and Rab10 precipitating with RILPL2 in cells expressing
R1441G LRRK2 (Fig 5D and E). These data are consistent with pRab10
binding both RILPL2 and MyoVa. Because RILPL2 can dimerize (Wei et al,
2013; Waschbüsch et al, 2020), it is possible that each half of the dimer
engages either MyoVa or pRab10 or both. Alternatively, pRab10 may
enhance the ability of MyoVa to bind RILPL2. Because pRab10 re-
localization of MyoVa and RILPL2 could occur in the absence of the
other partner, these possibilities were not studied further.
To demonstrate more directly the presence of a pRab10-specific
binding site in the MyoVa GTD, we used microscale thermophoresis
(MST) to monitor binding of purified proteins. Bacterially expressed,
purified Rab10 was phosphorylated in vitro using recombinant Mst3,
a kinase used previously to efficiently phosphorylate purified Rab8
Figure 2. PhosphoRab10 drives centriolar
relocalization of MyoVa and RILPL2.
(A) Localization of pRab10 and the centriole marker,
Centrin 3. HeLa cells were transfected with R1441G Myc-
LRRK2 and methanol fixed for staining with rabbit
anti-pRab10 and mouse anti-Centrin 3. The boxed area
is enlarged in the adjacent panels at right. Bar, 10 μM.
(B) HEK293T cells were transfected with R1441G
LRRK2, full-length MyoVa mCherry, and HA-RILPL2 for
16 h, treated ± 200 nM MLi-2 for 2 h and stained with
mouse anti-HA and rabbit anti-phosphoRab10. Bar,
10 μm. (C) Quantitation of cells with perinuclear RILPL2
from the experiment in (B) from two independent
experiments with >50 cells per condition. *0.027;
**0.0026 t test. (B, D) HEK293T cells depleted of MyoVa
were transfected with R1441G LRRK2 and HA-RILPL2
and stained for RILPL2 and pRab10 as in (B).
(E) Immunoblot of HEK293T cells depleted of MyoVa
using three shRNAs to create stable cell lines. Numbers
at left in this and subsequent figures represent mass
in kilodaltons. (F) Quantitation of perinuclear RILPL2 in
cells with and without MyoVa. No significant difference
was detected.
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and Rab10 proteins, uniquely at the same site as LRRK2 (Berndsen
et al, 2019; Waschbüsch et al, 2020). In vitro phosphorylation of
Rab10 proceeded linearly for ~100 min before reaching a plateau in
reactions containing 2 mM ATP and a ratio of 1:3 kinase:substrate at
27°C, as detected using a phosphoRab10-specific antibody (Fig 6A).
As expected, the reaction was ATP dependent (Fig 6B), and phos-
phorylation was efficient: ~90% of Rab10 was phosphorylated in
reactions containing Mst3 kinase as determined by PhosTag gel
electrophoresis that enables resolution of phosphorylated and
non-phosphorylated Rab10 proteins (Fig 6C).
Because it is difficult to purify significant quantities of fully active and
phosphorylated Rab10, we established a protocol that would enable us to
monitor in vitro pRab10 binding to MyoVa with minimal protein handling.
As outlined in Fig 6D, Rab10 was incubated for 120 min with Mst3 kinase
and ATP to achieve phosphorylation. NT-647 dye–labelled GTDwas added
for a subsequent 30-min binding reaction, followed by transfer of the
binding mix into capillaries for microscale thermophoresis analysis.
Control reactions contained all the same components except ATP during
binding; no signal was observed in reactions lacking Rab10 protein.
Phosphorylated Rab10 bound to purified MyoVa GTD with a KD of
475 ± 166 nM under these conditions (Fig 7A). This represents strong
binding as most Rab effectors bind Rabs with low micromolar af-
finities. Non-phosphorylated Rab10 assayed in parallel showed no
binding to GTD in reactions containing up to 18 μM GTD (Fig 7B). For
comparison, we also tested binding to another LRRK2 substrate,
Rab8A. The MyoVa GTD bound pRab8 ~14-fold less strongly and no
binding was detected to non-phosphorylated Rab8A protein (Fig 7C
andD). In summary, these in vitro binding assays confirm that pRab10
binds directly and with high affinity to the MyoVa GTD; pRab8A binds
much more weakly, consistent with the requirement for Rab10
protein in cells for MyoVa relocalization, despite the presence of
endogenous Rab8A protein (Fig 4).
Exogenous RILPL2 localizes to the mother centriole and blocks
ciliogenesis
We showed previously that overexpression of RILPL1 was sufficient
to block ciliogenesis in RPE and A549 cells (Dhekne et al, 2018). In
addition, LRRK2 generation of pRab10 was sufficient to block cil-
iogenesis but this required that cells contain endogenous RILPL1
protein (Dhekne et al, 2018). We thus tested the effect of exogenous
RILPL2 expression on primary cilia formation in the absence of
pathogenic LRRK2. hTERT-RPE cells were transfected with HA-tagged
RILPL2 and 24 h later, serum starved overnight to initiate ciliogenesis.
As shown in Fig 8A and B, even in the absence of pathogenic LRRK2,
RILPL2 expression strongly inhibited cilia formation. In addition, clonal
Figure 3. MyoVa exon D and its globular tail domain
drive Rab10 colocalization.
(A) MyoVa domain structure. MyoVa has a motor
domain (blue), isoleucine–glutamine (IQ) motifs, five
exons (A, B, C, D, E, gray) and a globular tail domain
(GTD, red). MyoVa ΔD lacks exon D and its Rab10
binding site; GTD indicates a construct that contains
only the MyoVa C-terminus (and pRab10 binding
site). (B) Full-length MyoVamCherry (MyoVa FL) or GTD-
mCherry were transfected into HEK293T cells plated on
collagen coated coverslips and imaged after 24 h.
Bars, 10 μm. (C) GFP-Rab10 was co-transfected with full
length MyoVa mCherry (top row) or Exon D deleted
MyoVa mCherry (bottom row) in HEK293T cells and
fixed after 24 h. Bar, 10 μm. (D) Myc-LRRK2 R1441G was
co-transfected with Exon D deleted-MyoVa mCherry in
HEK293T cells and fixed after 24 h. Cells were stained
for pRab10 (red), whereas MyoVa mCherry is pseudo-
colored (green). Bar, 10 μm. (E, left) Quantitation of
colocalization by Pearson’s method between GFP-
Rab10 and MyoVa mCherry ± Exon D (as indicated).
(E, Right) Quantitation of colocalization by Pearson’s
method between pRab10 and MyoVa mCherry ± Exon
D (as indicated). (F) Myc-LRRK2 R1441G was co-
transfected with GTD-mCherry in HEK293T cells and
fixed after 24 h. Cells were stained for pRab10 (red),
whereas GTD-mCherry is pseudo-colored (green). Bar,
10 μm. (G) Quantitation of colocalization by Mander’s
co-occurrence method where fraction pRab10 that
colocalizes with GTD is pRab10:GTD and fraction of GTD
that colocalizes with pRab10 is GTD:pRab10. Scale bars,
10 μm. Error bars indicate SEM from three
independent experiments with >50 cells per condition.
Significance was determined by t test; ***P = 0.0001; ns,
not significant with P = 0.0673.
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RILPL1 and RILPL2 knockout A549 cell lines were created using CRISPR-
Cas9. As we reported previously (Dhekne et al, 2018), endogenous
RILPL1 depletion in these cells dramatically increased cilia formation,
consistent with RILPL1’s role as a suppressor of ciliogenesis. In con-
trast, RILPL2 depletion did not influence ciliation in two independent
knockout lines (Fig 8C). Consistent with these results, MEFs generated
from homozygous RILPL2 knock-out embryos also showed no changes
in overall ciliogenesis (Fig 8B, right panel). Nevertheless, exogenous
expression of RILPL2 in these knockout MEF cells inhibited cilia for-
mation to an extent similar to that seen in RPE cells (Fig 8B).
Ciliogenesis is initiated by Tau tubulin kinase 2 (TTBK2)–mediated
phosphorylation events that drive the uncapping of CP110 from the
mother centriole (Spektor et al, 2007; Goetz et al, 2012). CP110 uncapping
also requires EHD1-dependent ciliary vesicle formation, a MyoVa
catalyzed process (Lu et al, 2015; Wu et al, 2018). We found that CP110
release required MyoVa in RPE cells under the conditions of our ex-
periments (Figs 8D and S4A). We also found that RILPL2 overexpression
blocked CP110 release (Fig 8D) but not TTBK2 recruitment to the mother
centriole (Figs 8E and S4A and B). Moreover, HA-RILPL2 expression
decreased theoverall concentrationofMyoVaat the centriole after 2 hof
serum starvation (Figs 8F and S4C). These data indicate that over-
expression of RILPL2 in some way interferes with the ability (or avail-
ability) of MyoVa to support the ciliary vesicle recruitment needed for
CP110 uncapping and subsequent ciliogenesis.
Wu et al (2018) reported that MyoVa knockout cells showed no
effect on CP110 release but had a striking defect in ciliary vesicle
association with mother centriole. This difference might be
explained by adaptation in knockout clones and/or a very short
time of serum starvation (30 min) in Wu et al (2018) (Fig S4B) versus
acute, siRNA-mediated MyoVa depletion and longer serum star-
vation (2 h in serum free medium) in our experiments (Fig 8D).
It was not possible to test if RILPL2 expression blocks ciliogenesis
in a MyoVa dependent manner because MyoVa knockdown alone
led to a block in CP110 capping (Fig 8D). Nevertheless, these ex-
periments suggest that exogenous overexpression of HA-RILPL2
blocks ciliogenesis by blocking MyoVa’s ability to participate in
ciliogenesis initiation.
Pericentriolar retention of MyoVa by pRab10
The strong concentration of pRab10, RILPL2, and MyoVa over the
centriole in pathogenic LRRK2-expressing cells suggested that
MyoVa may become sequestered by pRab10 and hindered from
contributing to ciliogenesis initiation. To explore this, we turned to
fluorescence loss in photobleaching (FLIP), a method that de-
creases the fluorescence of cytoplasmic proteins to permit an
estimation of live cell off-rates for proteins bound to a particular
compartment (Wüstner et al, 2012). As summarized in Fig 9A, live
Figure 4. Rab10 is essential for MyoVa globular tail
domain (GTD) relocalization.
(A) HEK293T cells depleted of Rab10 using two shRNAs
(KD1 and KD2) were transfected with MyoVa GTD and
R1441G LRRK2 for 16 h. Lentivirus carrying scrambled
shRNA-treated cells were used as controls. MyoVa GTD
and pRab10 were visualized as in Fig 2. (B) Cells were
transfected with Myc-Rab10 for 16 h and stained as in
(A). (C, D) Immunoblot analysis of Rab10, Myc-Rab10,
and tubulin loading control as in Fig 2. Rescue 1 (Res1)
and rescue 2 (Res2) refer to the different rescue
plasmids corresponding to the distinct shRNAs stably
expressed. (E) Quantitation of cells with pericentriolar
GTD without (left bars) or with (right bars) Myc-Rab10
rescue as indicated. Shown are the data from two
experiments (>200 cells per experiment).
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cells expressing mCherry-MyoVa constructs are bleached repeatedly
(300 times every 2 s) over a small region of the cell (boxed) distinct
from the perinuclear region of interest (ROI shown in dark red). Under
these conditions, the cytoplasmic concentration of the labeled protein
is unchangedbut the off rate fromanROI canbedeterminedover time.
A fluorescence stability reference is taken from an adjacent (non-
bleached) cell; fluorescence over the bleached region falls fastest,
followed by the adjacent cytoplasm and last by the ROI.
Using this method in HeLa cells expressing full-length MyoVa
mCherry and R1441G LRRK2, fluorescence loss over the ROI was
significantly slower (t1/2 = 272 s) than that over an adjacent area of
cytoplasm (t1/2 = 83 s) (Fig 9B–D). Importantly, this apparent re-
tention of MyoVa mCherry was ameliorated by addition of LRRK2
inhibitor MLi-2, a condition in which the MyoVa displayed the same
behavior as MyoVa in the adjacent cytoplasm (Fig 9B–D and Videos 1
and 2). Similar data and kinase activity dependence were obtained
for the MyoVa GTD, although the absolute retention was decreased
(t1/2 = 107 s versus 60 s; Videos 3 and 4), possibly because GTD is
monomeric whereas full length MyoVa is dimeric and avidity may
contribute to longer association with pRab10-decorated vesicles.
Mutational analysis of GTD binding to pRab10 showed that a GTD
R1528A mutation abolished co-localization with pRab10 in HEK293T cells
expressing R1441G LRRK2 protein; K1755A/K1757A or R1539/R1543A pro-
teins were unaltered in their localizations (Fig 10A and B). FLIP exper-
iments of cells expressing full-length MyoVa R1528A-mCherry showed
that only the wild-type protein was capable of the pericentriolar re-
tention detected by FLIP (Fig 10C and Video 5). The GTD containsmultiple
protein interaction interfaces; R1528 is important for GTD binding to
melanophilin (Pylypenko et al, 2013; Wei et al, 2013). In summary, these
experiments show that residue R1528 of the MyoVa GTD is critical for the
ability of MyoVa to be transiently retained at the mother centriole by
pRab10 protein. As discussed below, it is likely that this mode of re-
tention interfereswith thenumberofMyoVamolecules available todrive
normal ciliogenesis initiation.
Discussion
RILPL2 binds LRRK2-phosphorylated Rab10 with greater affinity
than non-phosphorylated Rab10 (Steger et al, 2017), and although
RILPL2 is known to bind MyoVa (Lisé et al, 2009) and contribute in
some way to cargo enrichment in ciliogenesis (Schaub & Stearns,
2013), little is known about its precise cellular function. We have
Figure 5. pRab10-specific interaction with the MyoVa
globular tail domain.
(A) MyoVa or MyoVa ΔD-mCherry and GFP-LRRK2-
R1441G were co-transfected into HEK293T cells; 24 h post
transfection, cells were incubated with 200 nM MLi-2
for 4 h. Cells were lysed in lysis buffer and 400 μg
extract immunoprecipitated with anti-RFP antibodies
on protein G beads. Samples (50% of IP and 15% of
input for all IPs in all panels) were immunoblotted
using anti-GFP, anti-RFP, anti-tubulin, anti-Rab10 and
anti-pRab10 antibodies. (A, B) Quantitation of the
relative amount of Rab10 (left) or pRab10 (right) co-
immunoprecipitated by MyoVa and MyoVa ΔD in (A).
Error bars indicate standard error of the mean from
two gels per co-IP. Significance was determined by t
test; ***P = 0.0003; ns, not significant with P = 0.295.
(C) MyoVa globular tail domain (GTD)-mCherry and
GFP-LRRK2 R1441G were co-transfected into HEK293T
cells. After 24 h, cells were incubated ± 200 nM MLi-2 for
4 h. Cells were lysed in lysis buffer and
immunoprecipitated with anti-RFP antibodies on
protein G beads. Samples were immunoblotted with
anti-GFP, anti-RFP, anti-Rab10 and anti-pRab10
antibodies. (D) RILPL2-GFP, MyoVa GTD-mCherry, and
Myc-LRRK2 R1441G were co-transfected into HEK293T
cells; 24 h post-transfection, cells were incubated ±
200 nM MLi-2 for 4 h. Extracts in lysis buffer were
immunoprecipitated with GFP-binding protein
Sepharose. Samples were immunoblotted with anti-
GFP, anti-RFP, anti-Rab10 and anti-pRab10 antibodies.
(D, E)Quantitation of the relative amount of total MyoVa
GTD (left) and Rab10 (right) co-immunoprecipitated
by RILPL2-GFP under the conditions indicated below
(E). Significance was determined by t test; *P = 0.021 and
0.035 (left) and P = 0.014 and 0.024 (right).
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shown here that RILPL2 is diffusely localized in RPE cells, and a
small portion moves to the mother centriole within ~3 h of serum
starvation. Others have shown that fluorescently tagged MyoVa
arrives within 30 min (Wu et al, 2018), thus a small fraction of RILPL2
follows with slower kinetics.
When expression of pathogenic R1441G/C LRRK2 increases
pRab10 on pericentriolar membranes, RILPL2 levels increase there
dramatically. MyoVa is normally broadly distributed throughout the
cytoplasm but it also concentrates in the pericentriolar region
when pRab10 levels increase. Concentration of MyoVa and RILPL2
both require Rab10 protein and can occur independent of one
another in cells expressing pathogenic LRRK2 kinase.
Our studies reveal that pRab10 interacts directly and tightly with
MyoVa’s GTD, and this interaction is likely responsible for the relo-
calization of MyoVa to the centriole in R1441G LRRK2-expressing cells.
This was unexpected, because pRab10 could have easily influenced
MyoVa localization indirectly via RILPL2 binding. However, recent mass
spectroscopy analysis shows that there is most likely not adequate
RILPL2 levels in cells to drive the levels of MyoVa relocalization we
detect: MEFs and 293T cells contain 4,777 and 13,065 copies of RILPL2,
respectively, and as much as more than 30 times more MyoVa protein
(161,976 and 125,128 copies; Nirujogi et al, 2021).
The GTD of MyoVa is a versatile cargo adaptor with independent
binding sites for multiple partners including RILPL2, Rab11A, Rab3A,
Spire, andmelanophilin. We showed that MyoVa’s R1528 (conserved
across tissue-specific isoforms), is critical for pRab10-dependent
relocalization. This interaction site is critical for MyoVa’s binding to
melanophilin in the specialized cell types that express melano-
philin (Wei et al, 2013; Pylypenko et al, 2013, 2016). Indeed, mutations
very close to this site have been shown to cause neurological
deficits in mouse models (Huang et al, 1998). That MyoVa is also a
Rab11 effector suggests that it functions as part of the Rab11:Rab8
cascade that is an important part of the early steps of cilia for-
mation (Knödler et al, 2010; Franco et al, 2014). Note that the Rab11
interface is not predicted to be altered by the R1528 mutation (Wei
et al, 2013; Pylypenko et al, 2013, 2016).
Our experiments show that MyoVa lacking exon D binds only to the
phosphorylated form of Rab10 protein, much less well to phosphoR-
ab8A, and not to non-phosphorylated Rab8. Despite its ability to bind
RILPL2, endogenous Rab8 which is also phosphorylated by R1441G/C
LRRK2 and located at the centriole (Purlyte et al, 2018; LaraOrdónez et al,
2019) was not sufficient to drive RILPL2 relocalization in cells depleted of
Rab10. Thismay be becauseMyoVa bindswith preference to pRab10 and
much less tightly to pRab8 (this work and Waschbüsch et al, 2020).
Because expression of MyoVa lacking exons D and F is specific to
endocrine, neuroendocrine and neuronal cells (Seperack et al, 1995),
Rab10 phosphorylation becomes a primary mode of regulation for
MyoVa in these cell types. Thus, the RH homology domain proteins
RILPL1, RILPL2, JIP3 and JIP4 increase their binding to Rab10 upon LRRK2
phosphorylation, whereas MyoVa lacking exon D engages a new
partner in the brain and endocrine cells. This may also have cell type-
specific implications for MyoVa motor activity (Cao et al, 2019).
Figure 6. In vitro phosphorylation of Rab10 by Mst3
kinase.
(A) Immunoblot of reactions containing purified Rab10
and Mst3 kinase, incubated together at 27°C with 2 mM
ATP. Reactions were stopped at indicated time points
by addition of 2× sample buffer and boiling for 5 min.
The reaction mixture (~150 ng of Rab10) was resolved by
12% SDS–PAGE. Samples were detected with anti-
Rab10 and anti-pRab10 antibodies as indicated.
Bottom, quantification of pRab10/Rab10 signal. (A, B)
Purified Rab10 Q63L and Mst3 were incubated ± 2 mM
ATP as in (A). (C) Purified Rab10-Q63L was mixed with
purified Mst3 in reaction buffer as indicated and
phosphorylated at 27°C for 2 h. The reaction mixture
(~200–250 ng of Rab10) was resolved on a Phos-tag gel
(10% gel with 40 μM Phos-tag, 80 μM MnCl2), transferred
onto a nitrocellulose filter after EDTA washes and
probed with anti-Rab10 antibody. Two separate Phos-
tag gel analyses are shown. (D) Schematic of Rab10
phosphorylation, binding and microscale
thermophoresis experiments. In +ATP condition, Rab10
and Mst3 are incubated for 2 h at 27°C. Pre-spun NHS-
Red Labeled globular tail domain (100 nM final) is
then added to serially diluted pRab10 reaction mixture
and incubated for 30 min in the dark at 25°C before
microscale thermophoresis is started (top). In -ATP
condition, the reaction mixture of Rab10 and Mst3 are
serially diluted, and NHS-red labeled globular tail
domain (100 nM final) is added immediately. The
samples are incubated for 30 min in the dark at 25°C
before microscale thermophoresis measurements are
started. In all phosphorylation reactions, final
concentrations of Rab10 and Mst3 were 20 and 7 μM,
respectively.
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Unlike loss of RILPL1 (Dhekne et al, 2018), knockout of RILPL2 does not
alter the ability of cells to form primary cilia in MEF or A549 cells.
Nevertheless, like RILPL1, expression of HA-RILPL2 blocks ciliogenesis,
perhaps by sequestering important components (such asMyoVa and/or
Rab10) in amanner that interferes with their ability to function. Whereas
RILPL1 overexpression blocks cilia formation by interfering with TTBK2
recruitment to the mother centriole (Sobu et al, 2021), RILPL2 over-
expression blocks cilia formation by a differentmechanism, as centriolar
TTBK2 levels were not changed upon RILPL2 overexpression. It seems
likely that in wild-type cells, RILPL2 overexpression interferes with
MyoVa’s ability to support early events in ciliogenesis that trigger CP110
uncapping independent of TTBK2.
Exogenous expression of pathogenic LRRK2 in 293T cells yields a large
fractionof total Rab10phosphorylation (Ito et al, 2016; Karayel et al, 2020).
However, ciliogenesis defects are also detected in knock-in MEF cells (cf.
Dhekne et al, 2018) that contain only a few percent of total Rab10 protein
phosphorylation, and in MEF cells depleted of the PPM1H phosphatase
that reverses LRRK2 phosphorylation (Berndsen et al, 2019). Low steady-
state Rab10 phosphorylation is also seen in cells derived from patients
carrying pathogenic LRRK2 mutations (Ito et al, 2016; Karayel et al, 2020).
Our FLIP experiments show strong retention of MyoVa over pericen-
triolar membranes and only monitor protein dissociation; reassociation
will also occur, yielding the high, steady state pericentriolar concentration
ofMyoVa proteinweobserve. Note that HeLa cells contain 45,719 copies of
MyoVa and 1.9 × 106 copies of Rab10 (Itzhak et al, 2016); similarly, MEFs
contain 10-fold less MyoVa than Rab10 (Nirujogi et al, 2021). Thus, even a
small percentage of total Rab10 phosphorylation could capture a sig-
nificant proportion of MyoVa protein. Such quantitative considerations
suggest that retention of proteins such as MyoVa by pRab10-decorated
vesicles can have profound consequences on the availability of proteins
to contribute to specific cellular processes. Altogether, these experiments
highlight the consequences of LRRK2-mediated Rab phosphorylation:
a single post-translational modification causes significant subcellular
redistribution and functional modulation in cells.
Materials and Methods
Reagents
MLi-2 LRRK2 inhibitor was obtained from Tocris Biosciences (Cat. no.
5756).
General cloning and plasmids
DNA constructs were amplified in Escherichia coli DH5α or stbl3 and
purified using mini prep columns (Econospin). DNA sequence
Figure 7. pRab10 binds the MyoVa globular tail domain.
(A, C)Microscale thermophoresis (MST) of the interaction between labeled MyoVa globular tail domain (GTD) with phosphorylated Rab10 or Rab8A. Purified Rab proteins
were phosphorylated with Mst3 kinase at 27°C for 2 h and then serially diluted; NHS-RED labeled GTD (final concentration 100 nM) was then added. (B, D) MST of MyoVa
GTD binding to unphosphorylated Rab10 or Rab8A. Graphs show mean and SEM from two independent measurements, each from a different set of protein preparations.
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verification of all plasmids was performed by Sequetech (http://
www.sequetech.com). Myc-LRRK2 was obtained from Addgene
(#25361) and the R1441G mutation introduced as described (Purlyte
et al, 2018). N-terminally tagged GFP-RILPL2 was cloned into
pcDNA5D using Gibson assembly, whereas HA-RILPL2 was
cloned into BamH1 and Not1 sites of pcDNA5D by restriction
cloning. Mouse MyoVa mCherry plasmid was a gift of Prof. Jim
Spudich (Stanford University). MyoVa GTD-mCherry (1,421–1,880)
and exon D (1,320–1,345) deletion mutants were made by site directed
mutagenesis. For bacterial expression, MyoVa GTD, Rab10-Q63L (1–181),
and Mst3 were kind gifts from Amir Khan (Trinity College, Dublin,
Ireland). Rab8a Q63L was cloned into a pET14b expression plasmid
using Gibson assembly. mKO2-PACT was generated by amplify-
ing the PACT domain of Pericentrin from cDNA of RPE cells as
described (Sobu et al, 2021). To generate a plasmid-encoding Rab10
shRNA#1 and #2-resistant wild-type Rab10, inverse PCR was per-
formed with primers (#1 F 59-ACTGCAAATATGGGATACAGCAGG-39, #1 R
59-TTAATCTTCTTTCCTTGTAATTCAACTG-39; #2 F 59-CACGGCATCAGG-
TTTTTTGAGACTAG-39, R 59-TTCTCTAGCGATCTGTTCTCCTTTTCC-39) myc-
Rab10 plasmid was used as a template, and the PCR product was
self-ligated with T4 DNA ligase, and T4 polynucleotide kinase before
transformation. Point mutants in MyoVa mCherry and GTD-mCherry
were introduced using PCR primers (R1528A - R 59-TACTTTCTGAT-
CATCGTTCAG, F 59-GCATCATTGCTGACATCAACAATTAAC; R1755A/1757A F
Figure 8. Exogenous RILPL2 blocks ciliogenesis.
(A) hTERT-RPE cells were transfected with HA-RILPL2
or mock transfected with lipofectamine and 24 h later,
serum-starved overnight to initiate ciliogenesis. Cells
were fixed with ice cold −20°C methanol for 2 min
and co-stained with rabbit anti-HA (green) or mouse
anti-Arl13b (red). Arrowhead indicates the likely
location of a RILPL2-positive centriole. Dotted lines
indicate cell outlines. Bar, 10 μm. (B) Quantitation of
cells with cilia ± HA-RILPL2 transfection. Error bars
represent SEM from two experiments, each with >25
cells per condition. Significance was determined by t
test; *P = 0.0164. (C) WT, RILPL1, and RILPL2 knockout
A549 cells were plated at 80% confluency. After 24 h,
cells were serum starved by transfer into 2% FBS-
containing medium for 48 h. Cells were fixed and
stained with mouse anti-Arl13b antibody for
quantitation of cells with cilia. Error bars represent
SEM from two experiments with >100 cells per condition
in each experiment. #1 and #2 indicate two different
A549 RILPL2 knockout clonal cell lines. (D) Quantitation
of cells with two CP110 dots indicating capped
centrioles in: (left) hTERT-RPE cells ± HA-RILPL2 for 24 h;
(right) hTERT-RPE cells ± MyoVa knock-down. Cells
were serum starved for 2 h, fixed with −20°C methanol
for 2 min and co-stained with anti-HA, anti-CP110 or
anti-CEP164/CP110 antibodies. Error bars represent
SEM from two experiments with >25 cells per condition
in each experiment. Significance was determined by t
test; **P = 0.0067 and 0.0045. (B, E) RPE cells expressing
HA-RILPL2 as in panel (B) were scored for TTBK2 at the
centriole after serum starvation as in Fig S4. Shown
are data from two independent experiments; >25 cells
per experiment. No significant difference was detected.
(B, F) RPE cells expressing HA-RILPL2 as in panel (B)
were scored for endogenous MyoVa at the centriole;
shown are data from two independent experiments; >50
cells per experiment for each condition. ****P <
0.0001 by t test.
phosphoRab10 sequesters MyoVa and RILPL2 Dhekne et al. https://doi.org/10.26508/lsa.202101050 vol 4 | no 5 | e202101050 10 of 16
59-GCTTTTGCAAGTGGCAAAGGCAACTGACGATGACGCAG, R 59-GCGTCA-
TCGTCAGTTGCCTTTGCCACTTGCAAAAGCTG). Base changes were con-
firmed by sequencing.
Cell culture, transfections, and ciliogenesis
HEK293T, A549, and hTERT-RPE cells were obtained from American
Type Culture Collection cultured in high-glucose DMEM with
10% fetal bovine serum. HEK293T cells were transfected with
Polyethylenimine HCl MAX 4000 (PEI) (Polysciences, Inc.) as
described (Reed et al, 2006). RPE cells were transfected with
Fugene HD (Promega), whereas A549 cells were transfected using
Lipofectamine 3000 according to the manufacturer. RPE cells stably
expressing mKO2-PACT were generated by lentivirus as described
by Sobu et al (2021). Cells were checked routinely for mycoplasma
using eitherMycoALertMycoplasmaDetection Kit (LT07-318; Lonza) or
PCR. Cells were grown to confluence in DMEMwith serum. hTERT-RPE
cells were ciliated by overnight serum starvation in DMEM medium
alone. For A549 cells, the cells were plated at 80% confluency and
24 h later, subjected to 2% serum for 48 h. To identify primary cilia, cells
were stained for a cilia marker, Arl13b. For monitoring CP110 release,
RPE cells were serum-starved for 1 h. Cultures of primary rat astrocytes
were obtained by antibody panning from rat pups as described (Foo
et al, 2011; Dhekne et al, 2018). In brief, 6–10 postnatal Sprague–Dawley
Figure 9. Fluorescence loss in photobleaching
analysis of MyoVa sequestration.
(A) Schematic of fluorescence loss in photobleaching
method. Cells are bleached 300 times over a region (~2%
of cell area, usually 2 × 2 μm) distinct from the region
of interest, once every (Sobu et al, 2020) Preprint 2 s.
This will decrease the cytoplasmic fluorescence over
the cell with time. Fluorescence over the bleached
region and the region of interest is monitored
continuously. (B, C) Legend for (C); (C) Relative
fluorescence intensity as a function of time for the
indicated regions. (C, D) Still micrographs from the
experiment shown in (C) (Video 1). MyoVa full length-
mCherry is shown in red; times (seconds) are
indicated.
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rat cortices were mechanically and enzymatically dissociated to
produce single cells. They were passed over successive, antibody-
coated negative panning plates to rid the suspension of microglia,
endothelial cells, and oligodendrocyte precursor cells before
selecting for astrocytes with an anti-ITGB5–coated plate. Astrocytes
that attached to the anti-ITGB5-coated plate were trypsinized and
plated onto poly-D lysine coated ACLAR coverslips. The cells were
incubated at 37°C with 10% CO2 and 90% O2 for 1–3 wk.
Lentivirus production
Lentivirus-based shRNA was used for gene knockdown of human
Rab10, human MyoVa, and mouse RILPL2. The lentiviral vector was
co-transfected with packaging vectors psPAX2, pMD2 VSV-G in
HEK293T cells using PEI. pLKO-puro-scramble was used as a control.
After 48 h, culture supernatants were collected and virus con-
centrated 10× overnight with Lenti-X concentrator (Clontech)
according to the manufacturer. Cells were transduced with virus
using polybrene (2 μg/ml). To make stable cells, infected cells were
selected with puromycin (1–2 μg/ml) 48 h after infection. Expression
of the target protein was verified by real time RT-PCR and/or
immunoblotting.
Gene knockdown
For silencing of the Rab10 gene, lentivirus pLKO.1-Rab10 shRNA was
used to infect HEK293T cells as described (Dhekne et al, 2018). For
human Rab10, pSIH vector was also used with a GFP reporter. The shRNA





CCATGTCACACTTGTTTTTG was cloned using EcoRI and BamHI re-
striction sites. For silencing human MyoVa in 293T cells, four shRNA
(#KD1—TRCN0000382038, KD2—TRCN0000381587, KD3—TRCN0000381168,
and #KD4—TRCN0000382222) were tested by Western blot. Because
robust down-regulation was obtained using #KD1 and #KD2, which
were used for further experiments. After 48 h, the cells were plated
onto coverslips for ciliogenesis or processed to determine knock-
down efficiency by qPCR. After 72 h, the cells were lysed for Western
Figure 10. PhosphoRab10 binding drives MyoVa
sequestration.
(A) Localization of MyoVa globular tail domain (GTD)
mutants in cells expressing R1441G LRRK2, monitored by
pRab10 staining. Cells were transfected with the
indicated mutant GTD constructs for 24 h and stained
as in Fig 2. (B) Quantitation of cells with clustered GTD
for the indicated plasmids shown below. Shown are
data from two independent experiments, >200 cells
each. *P = 0.013. (C) Fluorescence loss in photobleaching
analysis of cells expressing full length MyoVa or Full
length MyoVa harboring the indicated mutation as in
Fig 9.
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blot analysis of theMyoVa knock-down. For RILPL2 knockdown inMEFs,
two shRNA targeting mouse RILPL2 were obtained from Sigma-Aldrich
(TRCN0000176476, TRCN0000200318). The RILPL2 knockdown in MEFs
was verified by qPCR. Control shRNA sequence (cloned either into pSIH
or pLKO) was as in Addgene Plasmid #1864 and used as control.
Lysing and immunoblotting
Cells were lysed 24 h after transfection in ice-cold lysis buffer
containing 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1% (vol/vol)
Nonidet P-40 (NP-40), 5 mM MgCl2, 5 mM ATP, 1 mM EGTA, 1 mM
sodium orthovanadate, 50 mM NaF, 10 mM 2-glycerophosphate,
5 mM sodium pyrophosphate, 0.1 μg/ml mycrocystin-LR (Enzo Life
Sciences), 1 mM DTT, and EDTA-free protease inhibitor cocktail
(Sigma-Aldrich). Lysates were centrifuged at 13,800g for 15 min at
4°C and supernatants quantified by Bradford assay (Thermo Fisher
Scientific) and 60 and 400 μg of proteins used for immunoblotting
and co-immunoprecipitation assay, respectively. Antibodies were
diluted in a blocking buffer containing 5% milk in 0.05% Tween in
TBS and incubated overnight on the blots. Phos-tag (Fujifilm Wako)
gels were made according to the manufacturer using 40 μM Phos-
tag, 80 μMMnCl2 in a 10% acrylamide-bis-acrylamide gel. The Phos-
tag gel was washed for 15 min in 10 mM EDTA/Water, followed by
5-min wash in 1 mM EDTA/water and finally, distilled water.
Phosphorylated proteins were transferred to nitrocellulose for 20
min using a Bio-Rad Transblot system and staining with antibodies
as mentioned above.
Real-time PCR analysis
Lysis for qPCR was performed by solubilizing cells in 500 μl Trizol.
RNA was extracted according to the manufacturer. cDNA was
synthesized from 500 ng total RNA using Expand Multiscribe cDNA
synthesis kit (4368814) by Applied Biosystems. 1:10 diluted cDNAwas
then subjected to qPCR using Powerup Sybr green master mix
(Thermo Fisher Scientific) in an Applied Biosystem ViiA 7 qPCR
machine. qPCR primers for MyoVa were from Origene (hMyoVa Fw -
59 CTCACACGAACTCCTGCAAA, hMyoVa Rv - 59 AGGGGTAGTGGCATT-
GAGTG), for RILPL2 from Sigma-Aldrich (mRILPL2 Rv - 59 ATC-
CTTCTCTCTTCTTCCTC, mRILPL2 Fw - 59 AAGATGGTAGTGGATCTGAC).
The housekeeping gene primers were mouse HPRT (mHPRT Rv - 59
TTTACTGGCAACATCAACAG, mHPRT Fw - 59 AGGGATTTGAATCACGTTTG),
human GAPDH (hGAPDH fw - 59 GGATTTGGTCGTATTGGG, hGAPDH Rv -
59 GGAAGATGGTGATGGGATT). The mRNA expression analysis was
performed using the delta delta Ct method.
Co-immunoprecipitation
HEK293T cells expressing RILPL2-GFP, MyoVamCherry, ormyc-LRRK2
R1441G were harvested 24–48 h post-transfection and lysed. Equal
amounts of extract protein were incubated with GFP-binding
protein–conjugated agarose (ChromoTek) or anti-RFP antibody
(Anti-RFP RTU; Rockland Biosciences)–conjugated protein G beads
(Thermo Fisher Scientific) for 1 h at 4°C. Immobilized proteins were
washed four times with 1 ml lysis buffer, eluted with 2× SDS loading
buffer, and subjected to Bio-Rad Mini-PROTEIN TGX 4–20% gradient
gels. After transfer to nitrocellulose membrane and antibody
incubation, the blots were visualized using the LI-COR Odyssey
Imaging System.
Generation of knockout A549 cells
Rab10 knock-out (Ito et al, 2016) cell lines have been described
(Steger et al, 2017). The A549 RILPL1 knockout cell line has been
described (Dhekne et al, 2018), and the RILPL2 knockout cell lines
were made similarly using these guide pairs: sense A: GCCTG-
TTGGGCCGCGAGCTTA; antisense A: GATGTCATACACGTCCTCGG and
sense B: GTATGACATCTCCTACCTGTT, antisense B: GCCTCGGCGGT-
CAGCTGGAAG.
Generation of RILP2 knockout MEFs
RILPL2 knockout mouse line was originally acquired from The KOMP
Repository and is now available from MMRRC.org (Stock number:
049453-UCD). Rilpl2tm1a(KOMP)Wtsi mice were initially bred with
Taconic Total Body Cre mice expressing Cre recombinase (Model
12524) to produce the desired deletion. The mice were then bred
and maintained on a C57Bl/6j background to remove the Cre
recombinase allele. Genotyping of mice was performed by PCR
using genomic DNA isolated from ear biopsies and the following
primers, all at 10 pmol/μl: primer 1: 59-AGTTCCGTGCCCTTTTATAGCTG-
39, primer 2: 59-ACCACATGGCCTATTACCCAAACT-39, and primer 3: 59-
ATAATAACCGGGCAGGGGGG-39. PCR reactions were set up and run
using KOD Hot Start Polymerase standard protocol. PCR bands were
visualized on Qiaexcel (QIAGEN) using the standard DNA screening
kit cartridge. The wild-type sequence leads to a 508-bp species,
whereas the knockout produces a 697-bp species. Wild-type, het-
erozygous, and homozygous RILPL2 knock-out MEFs were isolated
from littermate-matched mouse embryos at day E12.5 generated
from crosses between RILPL2 knockout heterozygous mice. The
genotype of the cell was verified by PCR using genomic DNA as
described above.
Immunofluorescence staining and light microscopy
Cells were plated on collagen-coated coverslips transfected with
indicated plasmids. Cells were fixed with 3% paraformaldehyde for
20min, permeabilized for 3 min in 0.1% Triton X 100 (or 0.1% saponin
for anti-pRab10 antibody staining), and blocked with 1% BSA in PBS.
To stain centrioles with anti-CP110, anti-CEP164, or anti-EHD1, the
cells were fixed with ice-cold 100% methanol for 5 min and gently
washed with PBS followed by blocking with 1% BSA in PBS.
Antibodies were diluted as follows: mouse anti-Arl13b (1:2,000;
Neuromab), rabbit anti-Arl13b (1:1,000; Proteintech); mouse
anti-GFP (1:2,000; Neuromab); rabbit anti-RFP (1:1,000; Rockland Bio-
sciences); mouse anti-Myc (1:2, 9E10 Hybridoma culture superna-
tant, 1:1,000; BioLegend); rabbit anti pRab10 (1:1,000; Abcam); mouse
anti-CEP164 (1:1,000; Santa Cruz); rabbit anti-CP110 (1:2,000; Pro-
teintech); rabbit anti-EHD1 (1:1,000; Abcam), rabbit anti-LRRK2
(Clone UDD3; Abcam), rabbit anti-RILPL2 (1:500; Novus), chicken
anti-rootletin (1:1,000; Aves), and mouse/rabbit anti-HA (1:1,000;
Sigma-Aldrich). Anti-sera raised against RILPL2 in rabbit, which is
described by Steger et al (2017), was used for staining immuno-
panned primary rat astrocytes. Rabbit anti-MyoVa (1:1,000; Novus
phosphoRab10 sequesters MyoVa and RILPL2 Dhekne et al. https://doi.org/10.26508/lsa.202101050 vol 4 | no 5 | e202101050 13 of 16
Biologicals) was used for Western blots and immunofluores-
cence staining in 293T cells. Rabbit anti-MyoVa (1:1,000; Cell
Signaling Technology) was used for Western blot in RPE cells. Goat
anti-MyoVa (1:300, 17707; Santa Cruz) was used for staining primary
rat astrocytes. Highly cross adsorbed H+L secondary antibodies
(Life Technologies) conjugated to Alexa 488, Alexa 568, or Alexa 647
were used at 1:2,000. Nuclei were stained using 0.1 μg/ml DAPI
(Sigma-Aldrich).
Images were obtained using a spinning disk confocal microscope
(Yokogawa) with an electron multiplying charge coupled device
camera (Andor) and a 100× 1.4 NA oil immersion objective. Images
were analyzed using Fiji (https://fiji.sc/) and, as indicated, are
presented as maximum intensity projections. Colocalization was
quantified using the plugin JaCoP. Pearson’s and Mander’s corre-
lation coefficients were used to quantify colocalization between
fluorophores.
For time lapse imaging, 3 × 104 hTERT-RPE cells expressing mKO2-
PACT were seeded into eight-well glass bottom dishes (Nunc Lab-
Tek II Chambered Coverglass; Thermo Fisher Scientific) and cultured
overnight. Cells were transfected with GFP-RILPL2, then after 24 h,
the cells were serum-starved by replacing the media with Leibo-
vitz’s L-15 Medium, no phenol red (Thermo Fisher Scientific) without
serum. Starting 15 min after starvation initiation, images were
captured every 6 min using a spinning disk confocal with 63× 1.3 NA
glycerol immersion objective at 37°C.
FLIP was performed on a Leica SP8 WLL laser scanning confocal
microscope. MyoVa mCherry and GTD-mCherry cells were co-
transfected with GFP-LRRK2 (R1441G) in HeLa (Kyoto) cells and
imaged 16 h post-transfection. Cells were imaged at 256 × 256
resolution using bidirectional scanning and two-line averaging. A
1.5 × 1.5 μm square region ~7–8 μm distance from the perinuclear
region was bleached for 600 ms (five iterations) using an Argon 488
laser. MyoVa mCherry (full length) images were captured with the
standard photomultiplier tube using the 561 WLL laser (one iter-
ation) every 2 s and the bleach–image cycle repeated 300 times (250
times for GTD-mCherry). Images were analyzed using the Fiji multi-
measure tool on selected regions of interest. Adjacent non-ROI
values are averaged from four different cytosolic areas of the cell.
Data were plotted in GraphPad prism and T1/2 were obtained by
fitting one phase dissociation curves.
Protein expression and purification
His6 Rab10-Q63L (1–181), His6 Mst3, His6 Myosin Va GTD (1,464–1,855),
and His6 Rab8A Q63L were purified in E. coli BL21 (DE3 pLys) as
described by Berndsen et al (2019) and Waschbüsch et al (2020). In
brief, bacterial cells were grown at 37°C in Lucia Broth medium and
induced at A600 nm = 0.6–0.7 by the addition of 0.1 mM isopropyl-1-
thio-β-D-galactopyranoside (Gold Biotechnology) and harvested
after 18 h at 18°C. The cell pellets were resuspended in ice cold lysis
buffer (50 mM Tris, pH 8.0, 10% [vol/vol] glycerol, 250 mM NaCl,
10 mM Imidazole, 5 mMMgCl2, 0.5 mM DTT, 20 μM GTP, and EDTA-free
protease inhibitor cocktail [Roche]), lysed by one passage through
an Emulsiflex-C5 apparatus (Avestin) at 10,000 lbs/in2, and
centrifuged at 13,000 rpm for 25 min in a FiberLite F15 rotor (Thermo
Fisher Scientific). Clarified lysate was incubated with cOmplete Ni-
NTA resin (Roche) for 2 h at 4°C. Resin was washed three times with
five column volumes lysis buffer and eluted in 500 mM imidazole-
containing lysis buffer. The eluate was buffer exchanged and
further purified by gel filtration on Superdex-75 (GE Healthcare)
with 50 mM Hepes, pH 7.5, 5% (vol/vol) glycerol, 150 mM NaCl, 5 mM
MgCl2, 0.1 mM tris(2-carboxyethyl)phosphine (TCEP), and 20 μM GTP.
In vitro phosphorylation and microscale thermophoresis (MST)
His6 Rab10 Q63L 1–181 was incubated with His6-Mst3 at a molar ratio
of 3:1 (substrate:kinase). The reaction buffer was 50 mM Hepes, pH
7.5, 5% (vol/vol) glycerol, 150 mM NaCl, 5 mM MgCl2, 0.1 mM TCEP,
20 mM GTP, 6 μM BSA, 0.01% Tween-20, and 2 mM ATP (no ATP for
negative control). The reaction mixture was incubated at 27°C for
30 min–4.5 h in a water bath. Phosphorylation completion was
assessed by Western blot and PhosTag gel electrophoresis and
found to saturate at 2 h. Immediately after phosphorylation, the
samples were transferred to ice before binding determination.
Protein–protein interactions were monitored by MST using a
Monolith NT.115 instrument (Nanotemper Technologies). His6-
MyoVa GTD was labeled using RED-NHS 2nd Generation (Amine
Reactive) Protein Labeling Kit (Nanotemper Technologies). For all
experiments, the unlabeled protein partner was titrated against a
fixed concentration of the fluorescently labeled GTD (100 nM); 16
serially diluted titrations of the unlabeled protein partner were
prepared to generate one complete binding isotherm. Binding was
carried out in a reaction buffer in 0.5-ml Protein LoBind tubes
(Eppendorf) and allowed to incubate in the dark for 30 min before
loading into NT.115 premium treated capillaries (Nanotemper
Technologies). A red LED at 10% excitation power (red filter, exci-
tation 605–645 nm, emission 680–685 nm) and IR-laser power at
20% was used for 30 s followed by 1 s of cooling. Data analysis was
performed with NTAffinityAnalysis software (NanoTemper Tech-
nologies) in which the binding isotherms were derived from the raw
fluorescence data and then fitted with both NanoTemper software
and GraphPad Prism to determine the KD using a non-linear re-
gression method. The binding affinities determined by the two
methods were similar. Shown are averaged curves of pRab10 and
Rab10 from single readings from two different protein preparations.
Statistics
Graphs were made using GraphPad Prism 6 software. Error bars
indicate SEM. Unless otherwise specified, a t test was used to test
significance. Two tailed P-values < 0.05 were considered statistically
significant.
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Supplementary Information is available at https://doi.org/10.26508/lsa.
202101050.
Acknowledgements
This research was funded by a grant to SR Pfeffer from the US National
Institutes of Health (DK37332), and grants from the Michael J Fox Foundation
phosphoRab10 sequesters MyoVa and RILPL2 Dhekne et al. https://doi.org/10.26508/lsa.202101050 vol 4 | no 5 | e202101050 14 of 16
for Parkinson’s research. We are grateful to Dr. Dario Alessi for critical input
and enthusiastic support and Dr. Shahzad Khan for providing rat G2019S+/−
astrocytes.
Author Contributions
HS Dhekne: conceptualization, data curation, formal analysis, in-
vestigation, visualization, methodology, and writing—original draft,
review, and editing.
I Yanatori: conceptualization, data curation, formal analysis, in-
vestigation, visualization, methodology, and writing—original draft,
review, and editing.
EG Vides: conceptualization, data curation, formal analysis, in-
vestigation, visualization, methodology, and writing—review and
editing.
Y Sobu: conceptualization, data curation, formal analysis, investi-
gation, visualization, methodology, and writing—review and editing.
F Diez: resources.
F Tonelli: resources.
SR Pfeffer: conceptualization, data curation, formal analysis, su-
pervision, funding acquisition, visualization, project administration,
and writing—original draft, review, and editing
Conflict of Interest Statement
The authors declare that they have no conflict of interest.
References
Alessi DR, Sammler E (2018) LRRK2 kinase in Parkinson’s disease. Science 360:
36–37. doi:10.1126/science.aar5683
Assis LHP, Silva-Junior RMP, Dolce LG, Alborghetti MR, Honorato RV,
Nascimento AFZ, Melo-Hanchuk TD, Trindade DM, Tonoli CCC, Santos
CT, et al (2017) The molecular motor Myosin Va interacts with the cilia-
centrosomal protein RPGRIP1L. Sci Rep 7: 43692. doi:10.1038/srep43692
Berndsen K, Lis P, YeshawWM,Wawro PS, Nirujogi RS, WightmanM, Macartney
T, Dorward M, Knebel A, Tonelli F, et al (2019) PPM1H phosphatase
counteracts LRRK2 signaling by selectively dephosphorylating Rab
proteins. Elife 8: e50416. doi:10.7554/elife.50416
Cantalupo G, Alifano P, Roberti V, Bruni CB, Bucci C (2001) Rab-interacting
lysosomal protein (RILP): The Rab7 effector required for transport to
lysosomes. EMBO J 20: 683–693. doi:10.1093/emboj/20.4.683
Cao QJ, Zhang N, Zhou R, Yao LL, Li XD (2019) The cargo adaptor proteins
RILPL2 and melanophilin co-regulate myosin-5a motor activity. J Biol
Chem 294: 11333–11341. doi:10.1074/jbc.ra119.007384
Dhekne HS, Yanatori I, Gomez RC, Tonelli F, Diez F, Schüle B, Steger M, Alessi
DR, Pfeffer SR (2018) A pathway for Parkinson’s disease LRRK2 kinase
to block primary cilia and sonic hedgehog signaling in the brain. Elife
7: e40202. doi:10.7554/elife.40202
Foo LC, Allen NJ, Bushong EA, Ventura PB, Chung W-S, Zhou L, Cahoy JD,
Daneman R, Zong H, Ellisman MH, et al (2011) Development of a
method for the purification and culture of rodent astrocytes. Neuron
71: 799–811. doi:10.1016/j.neuron.2011.07.022
Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciraolo E, Martini M,
Monteyne D, De Luca E, Germena G, et al (2014) PI3K class II α controls
spatially restricted endosomal PtdIns3P and Rab11 activation to
promote primary cilium function. Dev Cell 28: 647–658. doi:10.1016/
j.devcel.2014.01.022
Fukuda M, Kuroda TS, Mikoshiba K (2002) Slac2-a/Melanophilin, the missing
link between Rab27 and myosin Va. J Biol Chem 277: 12432–12436.
doi:10.1074/jbc.c200005200
Gillingham AK, Munro S (2000) The PACT domain, a conserved centrosomal
targeting motif in the coiled-coil proteins AKAP450 and pericentrin.
EMBO Rep 1: 524–529. doi:10.1093/embo-reports/kvd105
Goetz SC, Liem KF, Anderson KV (2012) The spinocerebellar ataxia-associated
gene tau tubulin kinase 2 controls the initiation of ciliogenesis. Cell
151: 847–858. doi:10.1016/j.cell.2012.10.010
Huang JD, Mermall V, Strobel MC, Russell LB, Mooseker MS, Copeland NG,
Jenkins NA (1998) Molecular genetic dissection of mouse
unconventional myosin-VA: Tail region mutations. Genetics 148:
1963–1972. doi:10.1093/genetics/148.4.1963
Hume AN, Collinson LM, Hopkins CR, Strom M, Barral DC, Bossi G, Griffiths GM,
Seabra MC (2002) The leaden gene product is required with Rab27a to
recruit myosin Va to melanosomes in melanocytes. Traffic 3: 193–202.
doi:10.1034/j.1600-0854.2002.030305.x
Ito G, Katsemonova K, Tonelli F, Lis P, Baptista MAS, Shpiro N, Duddy G, Wilson
S, Ho PW-L, Ho S-L, et al (2016) Phos-tag analysis of Rab10
phosphorylation by LRRK2: A powerful assay for assessing kinase
function and inhibitors. Biochem J 473: 2671–2685. doi:10.1042/
bcj20160557
Itzhak DN, Tyanova S, Cox J, Borner GH (2016) Global, quantitative and
dynamic mapping of protein subcellular localization. Elife 5: e16950.
doi:10.7554/elife.16950
Jordens I, Fernandez-Borja M, Marsman M, Dusseljee S, Janssen L, Calafat J,
Janssen H, Wubbolts R, Neefjes J (2001) The Rab7 effector protein RILP
controls lysosomal transport by inducing the recruitment of dynein-
dynactin motors. Curr Biol 11: 1680–1685. doi:10.1016/s0960-9822(01)
00531-0
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